Tributyrin
CAS 60-01-5
Tributyrin (CAS 60-01-5) is a Phase 1 pharmaceutical compound with 2 bioactivity targets and 3 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 73024.11423728814 nM | 59 | - |
| - | Ki | 550.5 s-1 | 2 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| TAS2R14 TAS2R14 |
Agonist | 4.489999771118164 pEC50 | 24285091 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Tributyrin used for in pharmaceutical contexts?
Tributyrin (CAS 60-01-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Tributyrin?
Tributyrin has 3 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Diarrhoea, Feeling abnormal, Product use in unapproved indication. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Tributyrin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Glyceryl Tributyrate with EU status "permitted".
What clinical phase is Tributyrin in?
Tributyrin is rendered with ChEMBL max phase 1.